Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events
Ibrutinib vs chlorambucil in CLL patients not suitable for chemotherapy
How does an understanding of the microenvironment aid research in CLL?
Trial of ibrutinib with bendamustine and rituximab in CLL: results and study design
Importance of Bcl-2-targeted therapies
John Gribben et al.